biostudies-literatureLorthe ENational Research AgencyPREMUP FoundationFondation pour la Recherche MedicaleNational Institute of Health and Medical Research (INSERM)National Solidarity Fund for Autonomy (CNSA)French Health MinistryFondation de FranceNational Institute of CancerUniversite de GeneveFrench Institute of Public Health Research/Institute of Public HealthFondation des Treilles1560-1573https://www.ebi.ac.uk/biostudies/studies/S-EPMC9546066biostudies-literatureUnknown129(9)<h4>Objective</h4>To compare different antibiotic prophylaxis administered after preterm premature rupture of membranes to determine whether any were associated with differences in obstetric and/or neonatal outcomes and/or neurodevelopmental outcomes at 2 years of corrected age.<h4>Design</h4>Prospective, nationwide, population-based EPIPAGE-2 cohort study of preterm infants.<h4>Setting</h4>France, 2011.<h4>Sample</h4>We included 492 women with a singleton pregnancy and a diagnosis of preterm premature rupture of membranes at 24-31 weeks. Exclusion criteria were contraindication to expectant management or indication for antibiotic therapy other than preterm premature rupture of membranes. Antibiotic prophylaxis was categorised as amoxicillin (n = 345), macrolide (n = 30), third-generation BJOG : an international journal of obstetrics and gynaecologyAntibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort.PMC9546066Grant 00050329SPF 20160936356Grand Prix R18202KKIRESP TGIR 2009-01ANR-11-EQPX-0038Ramousset CBadessi ASchmitz TSagot PDiguisto CMaisonneuve EBedu ASamperiz SBahans CChalons SHilpert LRamful DBeuchee AMorel ODebeir MCarbonne BRoze JCMitanchez DKrim GFavre AGranier MCoquelin ACambonie GMonier IKhoshnood BRouget FCharkaluk MLEgo ABalamou CThiriez GPoulichet APladys PBoulot PLanger BGras-Le Guen CDuffaut CRoudaut SBonet MArnaud CLeguen ABoileau PTosello BLecomte BMatis JVieux RBranger BLaurence PLLorthe EPignol JHascoet JMD'Ercole CClaris OReboul LTran DBurguet ABlanc JGoffinet FSimeoni UDupuy RPMorville PJarreau PHLemery DRubio-Gurung SGouyon JBFresson JKhemache KPicaud JCGuillois BToure YDurrmeyer XDurox MRobillard PYCostedoat MJGascoin GSizun JRosenthal JMAstruc DColas NCouvreur SMilton ARannaud AMarchand-Martin LDreyfus MEPIPAGE-2 Obstetric Writing GroupBlondel BDesplanches TJoly-Pedespan LTorchin HKaminski MBenhammou VCharlier CRouger VVayssiere CBarbier CRousseau JTruffert PDaude HColine EFavreau ADupont CSaurel-Cubizolles MJFoix L'Helias LVendittelli FAlberge CCornu LGire CVerriere VBaby BBongain ABednarek NKayem GPierrat VAkowanou SMoras RCharlot FBinet MHPatural HSubtil DTsaoussis NMons FJanky EMarpeau LGondry JKuhn PDelorme PBrinis AMarret SBaron MAncel PYBeucher GChabanier PMorgan AZeitlin JLetouzey MHernandorena XDebillon TSaliba EBaud OSentilhes LSoupre DAyoubi MJoly NCans CLebeaux CDeschamps MWiner NfalseAntibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort.<h4>Objective</h4>To compare different antibiotic prophylaxis administered after preterm premature rupture of membranes to determine whether any were associated with differences in obstetric and/or neonatal outcomes and/or neurodevelopmental outcomes at 2 years of corrected age.<h4>Design</h4>Prospective, nationwide, population-based EPIPAGE-2 cohort study of preterm infants.<h4>Setting</h4>France, 2011.<h4>Sample</h4>We included 492 women with a singleton pregnancy and a diagnosis of preterm premature rupture of membranes at 24-31 weeks. Exclusion criteria were contraindication to expectant management or indication for antibiotic therapy other than preterm premature rupture of membranes. Antibiotic prophylaxis was categorised as amoxicillin (n = 345), macrolide (n = 30), third-generation 2022-01-01T00:00:00Z2022 Aug2025-04-22T01:58:16.432Z2025-04-05T20:10:09.669ZS-EPMC95460663495486710.1111/1471-0528.17081